We are pleased to share that we have completed enrollment in CANOPY, our Phase 3 clinical trial investigating VYD222 for the prevention of symptomatic #COVID19. Read our recent press release for more info: investors.invivyd.com/news-releases/…

New data continue to emerge that highlight the disproportionate impact that #COVID19 has on #immunocompromised (IC) people. The results from INFORM underscore the urgent need for new therapeutics that can protect the IC. bit.ly/47lO2XQ

We are pleased to announce positive initial results from our ongoing CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19. Learn more: investors.invivyd.com/news-releases/…

To protect vulnerable people from serious viral threats, we are taking a unique, platform-based approach that is grounded in a commitment to serial mAb candidate innovation and designed to anticipate and quickly respond to viral evolution. Learn more: invivyd.com/platform/#over…

We are pleased to announce that we have requested Emergency Use Authorization from the U.S. FDA for VYD222, a monoclonal antibody candidate, for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents. investors.invivyd.com/news-releases/…

We are proud to announce that our investigational monoclonal antibody authorized for emergency use by the U.S. FDA is now available for healthcare providers to order in the U.S. from a network of authorized specialty distributors. Learn more: invivyd.com/more-informati…. #SARSCOV2

The U.S. Centers for Medicare & Medicaid Services (CMS) has granted Healthcare Common Procedure Coding System (HCPCS) reimbursement codes covering our investigational monoclonal antibody authorized for emergency use by the U.S. FDA. investors.invivyd.com/news-releases/…. #monoclonals

Today we announced our intention to submit an emergency use authorization (EUA) application to the U.S. FDA for pemivibart for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people. investors.invivyd.com/news-releases/… #SARSCOV2

Join us on Thursday, May 9th at 4:30 PM ET for our earnings conference call where we will discuss our Q1 2024 financial results and recent business highlights.investors.invivyd.com/events/event-d…

On May 20th, we will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at 3:00 p.m. ET. Tune in live or watch a replay: investors.invivyd.com/events/event-d…

We are proud to have recently presented data at MAD-ID from our Phase 1 and Phase 3 clinical trial of VYD222 (pemivibart), our investigational monoclonal antibody authorized for emergency use by the U.S. FDA. Visit our website to learn more: invivyd.com/platform/#publ…

We are looking forward to #ASCO24. If you are attending, catch our poster presentation on 6/1 (abstract #2532) or visit our booth (#33169) to learn more about Invivyd and VYD222 (pemivibart), our investigational monoclonal antibody authorized for emergency use by the U.S. FDA.

We are excited to be participating in the 2024 AmericanTransplantCongress. If you are attending, catch our poster on 6/1 (abstract # A018) or visit our booth (#426) to learn about Invivyd and VYD222 (pemivibart), our investigational mAb authorized for emergency use by the FDA. #ATC2024Philly

#ThisJustIn: Together with our partners at Incyte, we’re pleased to announce that results from the pivotal AGAVE-201 trial were published in NEJM. Learn more: ir.syndax.com/news-releases/…

#NewsAlert: We are thrilled to announce a major milestone for Syndax. The U.S. Food and Drug Administration (FDA) has now approved the first and only therapy for relapsed or refractory acute leukemia with a KMT2A translocation. We would like to extend our heartfelt gratitude to

During National Cancer Research Month, we reflect on the importance of #cancer research and the progress we have made through the collaboration of many stakeholders across the medical research community, especially in certain types of cancers with urgent unmet need. In this

#NewsAlert: Today, we announced that our menin inhibitor has been included in the latest clinical practice guidelines for a second subset of patients. Learn more by accessing the press release below: ir.syndax.com/news-releases/…

#NewsAlert: We are thrilled to announce another major milestone for Syndax. The U.S. Food and Drug Administration (FDA) has now approved a second indication for revumenib. We would like to extend our sincere appreciation to the clinicians, investigators, Syndax employees, and

We’re thrilled to announce that Revuforj® (revumenib) has won the “Best New Drug” award during Citeline’s 2025 #ScripAwards! We’d like to extend our heartfelt gratitude to the Syndax employees, collaborators, and patients who made this achievement possible. Learn more below:

#NewsAlert: Today, we announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of our presentation at the 44th Annual J.P. Morgan Healthcare conference. 2025 was a transformational year for Syndax as we